Roche license revenue
The model assumed the full $700m upfront payment would be recognized this quarter. Nurix recognized $653.2m, contributing to the forecast overshoot.
Nurix Therapeutics
Oct 5, 2026, 12:32 AM PDT
Shortcut
5.30Shortcut
+3.8% vs Street
Street
5.11Street
Frozen October 4 snapshot
Real
4.73Actual GAAP diluted EPS
Shortcut loss
Street was closer. Shortcut’s EPS error was $0.57, compared with $0.38 for the Street.
Earnings release ↗How this result is scored
The score compares the original forecasts with reported GAAP EPS. The Street snapshot is labeled normalized, so matching adjustments remain unverified.
NRIX reported October 12 and is included in this week’s results. Its October 5 forecast and frozen October 4 Street estimate are unchanged.
Explore the model.
Open the assumptions and calculations behind this earnings forecast.
Behind the estimate.
Other assumptions
The model included $15.2m of collaboration revenue and Roche’s share of development costs.
Alternative scenario and tax assumption
Spreading the license payment over time produced a −$0.51 EPS scenario. The published $5.30 forecast assumed a 1.6% tax rate and no normalization adjustments.
Publication details
- Reporting period
- Q3 FY2026, ended 2026-08-31
- Reporting basis
- Normalized diluted EPS, USD per common share; zero adjustments assumed, consensus basis unverified
- Published
- Oct 5, 2026, 12:32 AM PDT
- Model / effort
- Opus 5.5 · High effort
Original forecasts, models and publication times remain on the record.